PharmaShots | Incisive News in 3 Shots

Subscribe Now

Boehringer Ingelheim

PharmaShots' Key Highlights of First Quarter 2023

PharmaShots' Key Highlights of First Quarter 2023

April 3, 2023

Boehringer Ingelheim’s Spevigo (spesolimab) Receives the Health Canada’s Marketing Authorization for Generalized Pustular Psoriasis

Boehringer Ingelheim’s Spevigo (spesolimab) Receives the Health Canada’s Marketing Authorization for Generalized Pustular Psoriasi...

March 24, 2023

Boehringer Ingelheim’s Spevigo (spesolimab) Receives EC’s Conditional Marketing Authorization for Generalized Pustular Psoriasis Flares

Boehringer Ingelheim’s Spevigo (spesolimab) Receives EC’s Conditional Marketing Authorization for Generalized Pustular Psoriasis F...

December 13, 2022

Boehringer Ingelheim Reports P-III (VOLTAIRE-X) Trial Results of BI 695501 (biosimilar, adalimumab) for Chronic Plaque Psoriasis

Boehringer Ingelheim Reports P-III (VOLTAIRE-X) Trial Results of BI 695501 (biosimilar, adalimumab) for Chronic Plaque Psoriasis

November 26, 2022

Boehringer Ingelheim and Eli Lilly Report P-III (EMPA-KIDNEY) Trial Results of Jardiance (empagliflozin) for Chronic Kidney Disease

Boehringer Ingelheim and Eli Lilly Report P-III (EMPA-KIDNEY) Trial Results of Jardiance (empagliflozin) for Chronic Kidney Diseas...

November 7, 2022

Insights+: The US FDA New Drug Approvals in September 2022

Insights+: The US FDA New Drug Approvals in September 2022

October 20, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
[email protected]
Newsletter

Our Information

Follow Us